Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apa/Enza Short Study
2023-506698-36-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- Dec 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apalutamide and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Erasmus MC. Primary endpoint: Time to clinical progression free survival (cPFS). Planned start Dec 2023; status: authorised.
02
Drugs
apalutamideenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-506698-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506698-36-00.